184 related articles for article (PubMed ID: 3894277)
1. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Cowan JD; Osborne CK; Neidhart JA; Von Hoff DD; Constanzi JJ; Vaughn CB
Invest New Drugs; 1985; 3(2):149-52. PubMed ID: 3894277
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer.
Allegra JC; Woodcock T; Woolf S; Henderson IC; Bryan S; Reisman A; Dukart G
Invest New Drugs; 1985; 3(2):153-61. PubMed ID: 3894278
[TBL] [Abstract][Full Text] [Related]
4. A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Bennett JM; Byrne P; Desai A; White C; DeConti R; Vogel C; Krementz E; Muggia F; Doroshow J; Plotkin D
Invest New Drugs; 1985; 3(2):179-85. PubMed ID: 3894279
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
Metz R; Delgado M; Keiling R; Cappelaere P; Armand JP; Prevot G; Misset JL; Grimbert J; Mathe G
Invest New Drugs; 1985; 3(2):163-6. PubMed ID: 4019119
[TBL] [Abstract][Full Text] [Related]
6. An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
De Jager R; Cappelaere P; Armand JP; Keiling R; Fargeot P; Bastit P; van Glabbeke M; Renard J; Earl H; Rubens R
Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1369-75. PubMed ID: 6542006
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.
Mouridsen HT; Cornbleet M; Stuart-Harris R; Smith I; Coleman R; Rubens R; McDonald M; Rainer H; van Oosterom A; Smyth J
Invest New Drugs; 1985; 3(2):139-48. PubMed ID: 4019118
[TBL] [Abstract][Full Text] [Related]
8. A comparison of mitoxantrone and doxorubicin in breast cancer.
Neidhart JA; Gochnour D; Roach R; Hoth D; Young D
J Clin Oncol; 1986 May; 4(5):672-7. PubMed ID: 3517241
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.
Henderson IC; Allegra JC; Woodcock T; Wolff S; Bryan S; Cartwright K; Dukart G; Henry D
J Clin Oncol; 1989 May; 7(5):560-71. PubMed ID: 2468745
[TBL] [Abstract][Full Text] [Related]
10. A comparative trial of mitoxantrone and doxorubicin in patients with minimally pretreated breast cancer.
Neidhart JA; Gochnour D; Roach RW; Young D; Steinberg JA
Semin Oncol; 1984 Sep; 11(3 Suppl 1):11-4. PubMed ID: 6385259
[TBL] [Abstract][Full Text] [Related]
11. Mitoxantrone versus doxorubicin in advanced breast cancer: a randomized cross-over trial.
Neidhart JA; Gochnour D; Roach RW; Steinberg JA; Young D
Cancer Treat Rev; 1983 Dec; 10 Suppl B():41-6. PubMed ID: 6362877
[No Abstract] [Full Text] [Related]
12. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer.
Holmes FA; Yap HY; Esparza L; Buzdar AU; Hortobagyi GN; Blumenschein GR
Semin Oncol; 1984 Sep; 11(3 Suppl 1):28-31. PubMed ID: 6385262
[TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.
Cornbleet MA; Stuart-Harris RC; Smith IE; Coleman RE; Rubens RD; McDonald M; Mouridsen HT; Rainer H; van Oosterom AT; Smyth JF
Eur J Cancer Clin Oncol; 1984 Sep; 20(9):1141-6. PubMed ID: 6541135
[TBL] [Abstract][Full Text] [Related]
14. First-line combination chemotherapy with mitoxantrone and cyclophosphamide in advanced breast cancer.
Periti P; della Cuna GR; Pannuti F; Mazzei T; Preti P; Martoni A; Mini E
Invest New Drugs; 1985; 3(2):167-71. PubMed ID: 4019120
[TBL] [Abstract][Full Text] [Related]
15. Mitoxantrone in advanced breast cancer--a phase II study with special attention to cardiotoxicity.
Coleman RE; Maisey MN; Knight RK; Rubens RD
Eur J Cancer Clin Oncol; 1984 Jun; 20(6):771-6. PubMed ID: 6540179
[TBL] [Abstract][Full Text] [Related]
16. Bisantrene, an active drug in patients with advanced breast cancer.
Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of a combination of doxorubicin and mitoxantrone in metastatic breast cancer.
Ford JM; Panasci L; Leclerc Y; Margolese R
Cancer Treat Rep; 1987 Oct; 71(10):921-5. PubMed ID: 3308079
[TBL] [Abstract][Full Text] [Related]
18. [Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
Tominaga T; Kitamura M; Hayashi K; Takahashi I; Kosaki G
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1669-74. PubMed ID: 6591857
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity.
Perren TJ; Blackledge G; Mould JJ; Chetiyawardana AD; Morrison M; Hancock A
Invest New Drugs; 1985; 3(2):173-7. PubMed ID: 3926713
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone as a first-line treatment of advanced breast cancer.
Landys K; Borgstrom S; Andersson T; Noppa H
Invest New Drugs; 1985; 3(2):133-7. PubMed ID: 4019117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
